Dismantling the Silos: How Pharma is Restructuring R&D for Generative AI

Executive Summary

The theoretical promise of generative AI in pharmaceutical R&D is finally translating into hard structural change. Top firms are realizing that AI’s true enterprise value cannot be unlocked by simply bolting new tools onto legacy processes. Instead, realizing a projected 40% reduction in time-to-market requires fundamentally dismantling traditional therapeutic silos and shifting capital expenditure from physical wet labs to computational power. The competitive moat is no longer just proprietary chemical libraries, but the speed, integration, and efficiency of the underlying AI operating model.

What Has Changed Recently

We are witnessing a definitive shift from isolated pilot projects to enterprise-wide operating model transformations. Novartis recently disbanded its legacy therapeutic discovery units in favor of a centralized, “AI-first” global hub. Simultaneously, Pfizer’s ‘Project Helix’ is replacing 30% of its physical pre-clinical wet labs with generative AI simulation hubs. Furthermore, Eli Lilly has implemented a hub-and-spoke reorganization that centralizes AI talent while distributing capabilities to clinical teams, effectively cutting Investigational New Drug (IND) application times in half. These are not software procurement updates; they are fundamental reorganizations of the R&D footprint.

The Core Strategic Challenge

The core challenge for executives is acknowledging that generative AI is fundamentally incompatible with sequential, siloed workflows. Historically, drug discovery moved linearly from one specialized department to the next, reliant on heavy capital expenditure in physical infrastructure. Integrating AI into this legacy structure only yields marginal efficiency gains. To capture exponential value, organizations must be willing to dismantle existing structures. This requires a difficult pivot in capital allocation, moving investment from physical real estate to computational infrastructure and a complete overhaul of talent integration, data governance, and cross-functional collaboration.

Three Strategic Pillars

Redefining Capital Expenditure What matters: Shifting R&D investment from physical infrastructure to computational power. Why it matters: Legacy fixed-cost structures, such as extensive physical wet labs, constrain the scalability of AI-driven simulations and limit operational agility. What stronger organizations do differently: They actively decommission redundant physical spaces to fund digital simulation hubs, treating compute and data architecture as their primary R&D assets.

Transitioning from Sequential to Parallel Workflows What matters: Replacing linear discovery pipelines with centralized, parallel ecosystems. Why it matters: Traditional sequential hand-offs create data bottlenecks and delay validation. Generative AI thrives on interconnected, cross-disciplinary data that can be processed simultaneously. What stronger organizations do differently: They dismantle traditional therapeutic-area silos, establishing centralized AI hubs capable of running parallel simulations that inform multiple drug programs at once.

Implementing Hub-and-Spoke Governance What matters: Centralizing core AI engineering while distributing capabilities to clinical teams. Why it matters: Highly specialized AI talent is scarce, yet deep clinical context is required to validate AI outputs and navigate complex regulatory pathways. What stronger organizations do differently: They build centralized centers of excellence to govern data and models, while deploying AI co-pilots directly to clinical teams to accelerate downstream processes like regulatory submissions.

The Forward View

As major pharmaceutical companies standardize their AI operating models, the industry will see a bifurcation between organizations that restructure and those that merely procure software. Leaders should monitor how regulatory bodies, such as the FDA and EMA, adapt their evaluation frameworks to audit therapeutics developed through parallel, generative AI hubs rather than traditional linear pathways. Do not overreact to the hype of AI curing diseases overnight; the projected timeline reductions will only materialize for firms that patiently and strategically rebuild their foundational R&D architecture. The next phase of AI maturity is not about the models you buy, but the legacy structures you are willing to dismantle.